TABLE 1.
Immunogensa |
|||||
Prime (day 0) | Boost (day 28) | Adjuvant | Dose (PFU) | Inoculation route | Challengeb (day 49) |
Ad5[P]OP | Ad5[P]OP | – | 5 × 108 | i.m. | Yes |
Ad5[PVP2]OP | Ad5[PVP2]OP | – | 5 × 108 | i.m. | Yes |
Ad5[P] | Ad5[P] | – | 5 × 108 | i.m. | Yes |
Ad5[G] | Ad5[G] | – | 5 × 108 | i.m. | Yes |
PBS | IV | + | 1 μg | i.p. | Yes |
IV, oil-adjuvanted inactivated commercial O1/Campos strain vaccine (Aftogen; BiogenesisBago, Argentina); P, P12A3C sequence from FMDV O1/Campos; G, green fluorescent protein; PFU, plaque-forming units. aDetail of the immunogens used in each experimental group. b104.5 TCID50 of FMD infective virus.